-
Life Sciences Expertise
Seth represents pharmaceutical, biotechnology, medical device, diagnostic, and other technology-based companies in a wide range of strategic transactions and corporate matters.
-
Extensive In-House Transactional Experience
Seth has more than 16 years of experience serving as in-house counsel at a global pharmaceutical company, where he advised on an array of strategic transactions and managed a team of lawyers and business professionals responsible for implementing intellectual property and business development transactions.
Seth Flaum is a partner in the New York office of Wilson Sonsini Goodrich & Rosati, where he is a member of the technology transactions practice. With more than 25 years of broad transactional experience, he represents life sciences companies in a wide range of strategic transactions and corporate matters.
Prior to joining the firm, Seth was the executive associate general counsel for Daiichi Sankyo, Inc., a global pharmaceutical company based in Japan, where he trained and managed a team of lawyers and business professionals responsible for implementing the company's global business development transactions. In this role, Seth counseled on strategic transactions, structuring, negotiating, and drafting strategic collaboration agreements, licensing agreements, research and development agreements, co-promotion agreements, commercialization agreements, option agreements, material transfer agreements, clinical trial agreements, CRO agreements, distribution agreements, manufacturing and supply agreements, and other transactions. He also has experience with public and private M&A transactions, and has advised on antitrust issues and filings, FINRA inquiries, SEC filings, and corporate governance matters.
Before joining Daiichi Sankyo, Seth was a senior associate at Ullman, Shapiro & Ullman, LLP in New York. Previously, he was general counsel at H&H Bagels, corporate counsel at Thompson Medical Company and Slim Fast Foods Company, and an associate at D'Erasmo, Shure & Perez in Rockville, Maryland.
Seth Flaum is a partner in the New York office of Wilson Sonsini Goodrich & Rosati, where he is a member of the technology transactions practice. With more than 25 years of broad transactional experience, he represents life sciences companies in a wide range of strategic transactions and corporate matters.
Prior to joining the firm, Seth was the executive associate general counsel for Daiichi Sankyo, Inc., a global pharmaceutical company based in Japan, where he trained and managed a team of lawyers and business professionals responsible for implementing the company's global business development transactions. In this role, Seth counseled on strategic transactions, structuring, negotiating, and drafting strategic collaboration agreements, licensing agreements, research and development agreements, co-promotion agreements, commercialization agreements, option agreements, material transfer agreements, clinical trial agreements, CRO agreements, distribution agreements, manufacturing and supply agreements, and other transactions. He also has experience with public and private M&A transactions, and has advised on antitrust issues and filings, FINRA inquiries, SEC filings, and corporate governance matters.
Before joining Daiichi Sankyo, Seth was a senior associate at Ullman, Shapiro & Ullman, LLP in New York. Previously, he was general counsel at H&H Bagels, corporate counsel at Thompson Medical Company and Slim Fast Foods Company, and an associate at D'Erasmo, Shure & Perez in Rockville, Maryland.
- J.D., Loyola Law School, 1994
- B.S., Finance, New York University Leonard N. Stern School of Business, 1991
- State Bar of New Jersey
- State Bar of New York
- J.D., Loyola Law School, 1994
- B.S., Finance, New York University Leonard N. Stern School of Business, 1991
- State Bar of New Jersey
- State Bar of New York
Illustrative Representations
Pharmaceutical and Diagnostic Collaboration Agreements
- Aytu BioPharma in its exclusive collaboration, distribution and supply agreement with Lupin Pharma Canada Ltd
- Ripple Therapeutics in it collaboration and option-to-license agreement with AbbVie
- BigHat Biosciences in its research collaboration with AbbVie
- Related Sciences in its drug discovery collaboration with Charles River
- Daiichi Sankyo in its global development and commercialization collaboration with AstraZeneca for TROP2-directed antibody drug conjugate (ADC) DS-1062*
- Daiichi Sankyo in its strategic coalition with CRO Syneos Health to develop an ADC oncology pipeline*
- Daiichi Sankyo in its global development and commercialization collaboration with AstraZeneca for HER2-directed ADC DS-8201 (Enhertu®)*
- Daiichi Sankyo in its clinical trial combination agreement with Merck for DS-1062 and Keytruda® and with Bristol-Myers Squibb for DS-8201 (Enhertu®) and Opdivo®*
- Daiichi Sankyo in its strategic collaboration in Japan with Kite Pharma Inc. for a cell therapy product ( Yescarta®)*
- Daiichi Sankyo in multiple collaboration agreements with Portola Pharmaceuticals and with Perosphere (acquired by AMAG) for factor Xa reversal agents*
- Daiichi Sankyo in its strategic collaboration and co-promotion agreement with AstraZeneca for a small molecule product for opioid induced constipation (Movantik®)*
- Daiichi Sankyo in its strategic collaboration and option agreement with Amplimmune (acquired by AstraZeneca) for an immune modulation therapy*
- Daiichi Sankyo in its exclusive licensing agreement in Japan with Coherus Biosciences for select biosimilars*
- Daiichi Sankyo in multiple exclusive worldwide licensing agreements with ArQule (acquired by Merck) for small molecule oncology products*
- Daiichi Sankyo in its authorized generic distribution agreements with Ranbaxy Pharmaceuticals and Sun Pharmaceuticals*
- Daiichi Sankyo in its global collaboration with Invivoscribe and other prominent diagnostic companies for companion diagnostics*
- Daiichi Sankyo in its research collaboration with DarwinHealth*
- Daiichi Sankyo in its multiple alliance agreements with Sanford-Burnham Medical Research Institute*
- Venture Science Laboratories in its drug discovery research collaboration with University of California San Francisco (UCSF) to develop novel therapeutics and molecular diagnostics for multiple neurodegenerative diseases*
Mergers and Acquisitions and Divestitures
- IVIVA in its acquisition by United Therapeutics
- Plexxikon in its sale of a portfolio of small molecule oncology therapeutics and other assets to Opna Bio*
- Daiichi Sankyo in the divestiture of its pharmaceutical packaging plant and laboratory to Sharp Packaging Services, a division of UDG Healthcare*
- Daiichi Sankyo in its acquisition of Ambit Biosciences*
- Daiichi Sankyo in its sale of Ranbaxy Laboratories to Sun Pharmaceuticals *
- Daiichi Sankyo in its acquisition of Plexxikon*
* Denotes experience prior to joining Wilson Sonsini in 2022.
Illustrative Representations
Pharmaceutical and Diagnostic Collaboration Agreements
- Aytu BioPharma in its exclusive collaboration, distribution and supply agreement with Lupin Pharma Canada Ltd
- Ripple Therapeutics in it collaboration and option-to-license agreement with AbbVie
- BigHat Biosciences in its research collaboration with AbbVie
- Related Sciences in its drug discovery collaboration with Charles River
- Daiichi Sankyo in its global development and commercialization collaboration with AstraZeneca for TROP2-directed antibody drug conjugate (ADC) DS-1062*
- Daiichi Sankyo in its strategic coalition with CRO Syneos Health to develop an ADC oncology pipeline*
- Daiichi Sankyo in its global development and commercialization collaboration with AstraZeneca for HER2-directed ADC DS-8201 (Enhertu®)*
- Daiichi Sankyo in its clinical trial combination agreement with Merck for DS-1062 and Keytruda® and with Bristol-Myers Squibb for DS-8201 (Enhertu®) and Opdivo®*
- Daiichi Sankyo in its strategic collaboration in Japan with Kite Pharma Inc. for a cell therapy product ( Yescarta®)*
- Daiichi Sankyo in multiple collaboration agreements with Portola Pharmaceuticals and with Perosphere (acquired by AMAG) for factor Xa reversal agents*
- Daiichi Sankyo in its strategic collaboration and co-promotion agreement with AstraZeneca for a small molecule product for opioid induced constipation (Movantik®)*
- Daiichi Sankyo in its strategic collaboration and option agreement with Amplimmune (acquired by AstraZeneca) for an immune modulation therapy*
- Daiichi Sankyo in its exclusive licensing agreement in Japan with Coherus Biosciences for select biosimilars*
- Daiichi Sankyo in multiple exclusive worldwide licensing agreements with ArQule (acquired by Merck) for small molecule oncology products*
- Daiichi Sankyo in its authorized generic distribution agreements with Ranbaxy Pharmaceuticals and Sun Pharmaceuticals*
- Daiichi Sankyo in its global collaboration with Invivoscribe and other prominent diagnostic companies for companion diagnostics*
- Daiichi Sankyo in its research collaboration with DarwinHealth*
- Daiichi Sankyo in its multiple alliance agreements with Sanford-Burnham Medical Research Institute*
- Venture Science Laboratories in its drug discovery research collaboration with University of California San Francisco (UCSF) to develop novel therapeutics and molecular diagnostics for multiple neurodegenerative diseases*
Mergers and Acquisitions and Divestitures
- IVIVA in its acquisition by United Therapeutics
- Plexxikon in its sale of a portfolio of small molecule oncology therapeutics and other assets to Opna Bio*
- Daiichi Sankyo in the divestiture of its pharmaceutical packaging plant and laboratory to Sharp Packaging Services, a division of UDG Healthcare*
- Daiichi Sankyo in its acquisition of Ambit Biosciences*
- Daiichi Sankyo in its sale of Ranbaxy Laboratories to Sun Pharmaceuticals *
- Daiichi Sankyo in its acquisition of Plexxikon*
* Denotes experience prior to joining Wilson Sonsini in 2022.
Adzenys XR-ODT extended-release orally disintegrating tablets is a prescription medicine used for the treatment of attention deficit hyperactivity disorder (ADHD) in patients 6 years and above and the only brand FDA-approved as bioequivalent to Adderall XR®. Cotempla XR-ODT is the only extended-release orally disintegrating tablet methylphenidate and is FDA-approved as a once-daily ADHD treatment for patients 6 to 17 years of age. Aytu's ADHD portfolio has experienced rapid growth over the past two years, with prescriptions increasing 16.5 percent during that time. This agreement extends Aytu's reach through the expansion into one of the world's largest ADHD markets outside the United States. In 2023, the Canadian ADHD stimulant market recorded 4.5 million units and $1.1 Billion CAD in gross sales. (Source: IQVIA Canada). Lupin will seek local regulatory approvals and marketing authorizations for both Adzenys XR-ODT and Cotempla XR-ODT, which is expected to occur over the next 18 to 24 months.
- Privacy Policy
- Terms of Use
- Accessibility